First Light Diagnostics,
Speeding Response For COVID-19 Patients with Secondary Infections
As our country nears 100,000 deaths attributable to COVID-19 and its complications, one thing has become clear. Just as with the 1918 Spanish flu epidemic, many patients are dying from ventilator-associated pneumonia and other hospital-acquired bacterial infections in addition to coronavirus. This has been a significant problem even before the current pandemic. According a National Institute of health study, between 250,000 and 300,000 cases of ventilator-associated pneumonia per year occur in the United States alone.
As with any bacterial infection, rapid identification and treatment is key to survival. First Light Diagnostics has answered that need for speed with the development of a state-of-the-art system that can identify bacterial pathogens and determine antimicrobial susceptibility in hours instead of days. The Multipath™ Analyzer uses innovative technology that allows clinicians to test for infection without the time-consuming step of growing cultures. Being able to take primary patient samples directly into Antimicrobial Susceptibility Testing saves valuable time and is a game-changer for treatment.
This short video shows how the Multipath Analyzer can save lives and reduce the single greatest expense to hospitals, today and in the years ahead, while also helping reduce antibiotic resistance.
The First Light Multipath Analyzer is a fully automated benchtop system that provides true “sample to answer” testing capabilities. It is designed to meet the demands of busy hospital and clinical laboratories that are challenged to provide results faster, with fewer resources. Simply load the test cartridge on the analyzer and walk away.
The Multipath Analyzer offers several significant benefits:
- High throughput: The MultiPath platform provides laboratories the horsepower to perform up to 200 pathogen identification tests or 40 antimicrobial susceptibility tests per 8-hour shift. This throughput will support the workflow of even the highest volume microbiology laboratories
- Full automation: Covers the entire sampling process from sample loading, barcode scanning, results reporting, LIS data transfer, and cartridge disposal.
- Multi-sample testing: Features a 20-sample capacity with continuous sample throughput capability.
- Affordability: The MultiPath analyzer is designed with value and performance in mind, and First Light tests offer labs a combination of high-performance and cost-effective testing capabilities.
- On-demand testing: A true “load and go” testing system that is walk up ready when you need it.
- Any test type at any time: A single cartridge design for the full menu of First Light tests.
- Touchscreen operation: An intuitive yet powerful software user interface provides a simple, flexible user experience.
- Connectivity: Supports bi-directional LIS connectivity, and USB ports for easy data transfer.
Currently in pre-market testing with beta customers and with FDA Clearance pending, First Light’s Multipath Analyzer is poised to become a primary tool in the fight against hospital acquired infections and antibiotic resistance.
To find out more about their innovative approach to one of the major challenges faced by hospitals and clinics across the globe, visit www.firstlightdx.com.
To learn how you can invest in making the vision a reality, contact First Light President and CEO, David Macdonald at email@example.com.
All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.